2 TB For Life! 65% Off pCloud Lifetime

Pfizer claims New Pfizer vaccine will immunise babies BEFORE THEY ARE BORN…

“Pfizer have declared they will be giving out a new vaccine called the PH111 to be given specifically to pregnant women, which will be immunising a newborn baby while still in the uterus”

 

On November 1, 2022, Pfizer announced its maternal vaccine against the respiratory syncytial virus (RSV) to be almost 82% effective in protecting infants for the first 90 days of life against severe illness due to RSV. Furthermore, the vaccine was found to remain 69.4% effective in preventing severe RSV illness throughout the first six months of life.

Pfizer’s RSVpreF vaccine

There remains no specific treatment available for RSV infection; therefore, children infected with this virus, including those hospitalized with severe illness, typically receive symptomatic care until the infection eventually clears their systems. The lack of both preventative and antiviral treatments available for RSV has led Pfizer to develop and test the efficacy of a bivalent RSV perfusion vaccine candidate known as RSVpreF or PF-06928316. Source: news-medical.net

Also

Pfizer says its RSV vaccine protects against severe illness in older adults
Respiratory syncytial virus occurs each year during fall, winter and spring and can be deadly for older people. Pfizer said it plans to seek FDA approval for the new shot soon.

Pfizer’s experimental vaccine for a respiratory virus called RSV was nearly 86% effective in preventing severe illness in a late-stage clinical trial of older adults, the company announced in a release Thursday. Source

 

Furthermore…

Pfizer confirmed plans on November 1, 2022, plans to submit a Biologics License Application to the U.S. FDA by the end of 2022 for the vaccine candidate, followed by other regulatory authorities in the coming months.

In November 2018, the FDA granted Fast Track status to RSVpreF.

A $27.5 million grant from Bill & Melinda Gates Foundation to Pfizer on September 28, 2022, will support the development of an affordable multidose vial for delivery of the RSV vaccine candidate in lower-income countries via public sector purchasers, including Gavi. Source

They want to have everyone poked “from womb to tomb.” Literally, and rather quickly.

Leave a Reply